Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib in Juvenile Idiopathic Arthritis (JUVE-BASIS)
NCT03773978Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2018
- Primary completion
- Jan 2022
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Antibody-Based Therapeutics
- Countries
- 20
01
Overview
Phase 3, randomised, double-blind trial in juvenile idiopathic arthritis (JIA) comparing Baricitinib with Placebo (2 arms). Primary endpoint: Time to Disease Flare. Started Dec 2018; status: completed.
02
Drugs
baricitinib
03
Conditions
juvenile idiopathic arthritis (JIA)
Beyond the preview
Go deeper on NCT03773978.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03773978.